Analytical technology company SCIEX has announced a co-marketing agreement with EluciData, a company that provides tools for metabolomics data processing. Under the agreement, EluciData and SCIEX will promote EluciData’s integrated Omics platform, called Polly, in conjunction with SCIEX technologies, including TripleTOF, X500R, and QTRAP, as well as Differential Ion Mobility technology.
The co-marketing arrangement is designed to allow the two companies to address the common problem faced by metabolomics researchers of how to process metabolomics data derived from a diverse range of workflows.
“Improving the efficiency of metabolomics workflows is critical if academic researchers and pharma customers want to advance precision medicine,“ said Mark Cafazzo, director of strategic market management at SCIEX in a press release. “The use of Polly with SCIEX metabolomics workflows accelerates their capabilities and empowers them with spending more time on the biology than crunching data through fragmented software tools. By partnering with EluciData and applying Polly to SCIEX next-generation metabolomics solutions, we help scientists address the challenges they face every day.“
EluciData’s Polly is a vendor-neutral, integrated omics platform that standardizes and streamlines metabolomics data analysis workflows. It also integrates other omics data, to allow researchers to develop a better understanding cellular phenotypes. Hosted in the cloud, EluciData allows for researchers to modify its operation, as needed, to support customized omics processing pipelines, comprehensive bioinformatics analysis capabilities, real-time scientific collaboration, and project management.
Polly MetScape, a global metabolomics profiling data analysis workflow, is compatible with data acquired in SWATH Acquisition that allows users to collect MS and MS/MS of every detectable peak in their sample, to create a digital map of the metabolome. The PollyPhi Workflow enables hypothesis validation, allowing scientists to go from pathways to highlighting changes in enzyme function by analyzing flow of labels through metabolites to validate hypotheses.
“Manual mass spectroscopic flux analysis, and especially MS/MS analysis for our MIMOSA workflows, is incredibly time and thought demanding, is prone to user errors, and limits our output,” said Dr. Richard Kibbey, associate professor of medicine at Yale Medical School. “PollyPhi provides a soup to nuts analysis of our Differential Ion Mobility MS/MS data that greatly accelerates this process, freeing the bright minds and hands for more appropriate tasks. We use PollyPhi for analysis of data generated from our SCIEX QTRAP 5500 and TripleTOF 6600 instruments. It has transformed my lab.”
